Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Rating of “Reduce” by Brokerages

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have been given a consensus recommendation of “Reduce” by the eight ratings firms that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $18.8571.

Several equities analysts recently weighed in on the company. Wall Street Zen downgraded Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Citigroup reiterated a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Truist Financial increased their target price on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. BMO Capital Markets started coverage on Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. Finally, Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th.

Institutional Trading of Integra LifeSciences

Institutional investors have recently added to or reduced their stakes in the stock. Paradigm Capital Management Inc. NY lifted its holdings in Integra LifeSciences by 50.6% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after buying an additional 1,347,700 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Integra LifeSciences by 12.4% during the 2nd quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after acquiring an additional 160,814 shares in the last quarter. Bank of America Corp DE boosted its holdings in Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares during the period. Systematic Financial Management LP raised its holdings in shares of Integra LifeSciences by 4.5% during the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock worth $13,769,000 after purchasing an additional 48,094 shares during the period. Finally, Invenomic Capital Management LP raised its holdings in shares of Integra LifeSciences by 78.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock worth $13,115,000 after purchasing an additional 463,729 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

IART stock traded down $0.04 on Friday, hitting $15.06. The company’s stock had a trading volume of 107,242 shares, compared to its average volume of 874,916. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -167.20, a price-to-earnings-growth ratio of 0.83 and a beta of 1.21. The firm has a 50 day moving average of $17.41 and a two-hundred day moving average of $14.73. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $20.49.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The business had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Equities analysts predict that Integra LifeSciences will post 2.46 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery and wound care. Its technologies are designed to help healthcare professionals treat complex conditions, repair damaged tissue and support surgical procedures.

The company’s portfolio includes dural repair products and other neurosurgical implants, surgical instruments, regenerative tissue technologies, wound-care products and solutions for extremity reconstruction.